CLDX

Over the past six months, Celldex Therapeutics experienced several stock events: on September 22, 2026, positive Phase 3 results for Barzolvolimab in CSU were announced, yet the market reacted negatively, causing a stock decline. The company presented at an investor conference on September 8, 2026, and reported second-quarter financial results and a corporate update on August 6, 2026. On July 21, 2026, a Phase 2 study of Barzolvolimab in prurigo nodularis failed to meet its endpoints, leading to program discontinuation and a stock price drop. A planned CFO transition was announced on July 15, 2026, and in April 2026, the company raised over $300 million, ensuring strong liquidity. As of September 30, 2026, the stock saw an 18.22% decline in 30-day share price return, despite a 19.99% year-to-date increase and a 28.15% one-year total shareholder return.